Key Takeaway: Nurix is focused on developing innovative therapies to combat cancer and autoimmune diseases. The company emphasizes the importance of novel scientific insights and has a multi-modal portfolio of assets. Their approach includes addressing challenges related to acquired inhibitor resistance and exploring new functions of BTK in clinical settings.
Price reaction · baseline $5.26 (2023-10-30 close) · hit pre-market · 3 other NRIX headline(s) in the window, move may be shared
day 0 close
+6.3%
day 1
+7.6%
day 3 · peak
+22.8%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.